BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CS32582 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CS32582\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07129382-1857@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20270918
DTEND;VALUE=DATE:20270919
SUMMARY:CS32582: Phase 1/2 readout est. (NCT07129382)
DESCRIPTION:CS32582\, phase 1/2\, Psoriasis.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of CS32582 in Participants With Moderate to Severe P
 laque Psoriasis\nEstimated primary completion: 18 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cs32582#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07129382
URL:https://assetmemo.bio/drug/cs32582#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
